Treatment features of adult patients with acute myeloid leukemia during the COVID-19 pandemic
D. E. Gagloeva,
E. N. Misyurina,
T. N. Tolstykh,
E. A. Baryakh,
K. V. Yatskov,
E. A. Karimova,
A. B. Makeshova,
M. A. Mingalimov,
T. S. Chudnova,
D. D. Ivanova,
A. I. Koneva,
O. L. Kochneva,
E. N. Zotina,
E. Yu. Grishina,
L. T. Shimanovskaya,
V. N. Yakimets,
E. I. Zhelnova https://doi.org/10.17650/1818-8346-2023-18-4(Suppl)-40-44
Abstract
Background. Acute myeloid leukemia (AML) is a highly aggressive oncological disease of the blood and bone marrow, requiring extremely toxic chemotherapy and massive supportive treatment to achieve stable remission. Currently, there is no work to provide medical care to these patients with a high risk of coronavirus infection. This paper presents treatment results of a large AML patient cohort during the COVID-19 pandemic.
Aim. To assess the clinical features of coronavirus infection in AML patients.
Materials and methods. A retrospective cohort study included patients hospitalized at City Clinical Hospital No. 52 (Moscow) between March 2020 and March 2022. Study inclusion criteria: 1) AML diagnosed within the last 3 years before the development of the COVID-19 pandemic; 2) age over 18 years; 3) laboratory confirmed SARS-CoV-2. AML status (newly diagnosed AML, relapse/refractory disease, remission), age, gender, comorbidity index, previous AML therapy and its outcomes were also assessed.
Results. Among 218 patients with acute leukemia, 60 (27.5 %) patients had acute lymphoid leukemia, 158 (72.5 %) had AML. Patients with acute promyelocytic leukemia were allocated to a separate group - 20 (9 %) patients. The statistical data of the remaining 138 (63.5 %) patients with AML, their survival and mortality rates were assessed, and the main prognostic factors influencing the mortality and severity of coronavirus infection were identified. Also, our own results were compared with world statistics.
Conclusion. Coronavirus infection in AML patients significantly worsens the prognosis. The main factors influencing the severity of coronavirus infection and survival and mortality rates are age, somatic status of patients due to the presence of concomitant chronic diseases, the development of deep hypoplasia of hematopoiesis, and the active AML status (disease onset or resistant course).
About the Authors
D. E. Gagloeva
City Clinical Hospital No. 52, Moscow Healthcare Department; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University); State Scientific Center of the Russian Federation – A.I. Burnazyan Federal Medical Biophysical Center, Federal Medical and Biological Agency of Russia
Russian Federation
Russian Federation
Diana E. Gagloeva.
3 Pekhotnaya St., Moscow 123182; Build. 2, 8 Trubetskaya St., Moscow 119991; 46 Zhivopisnaya St., Moscow 123098
E. N. Misyurina
City Clinical Hospital No. 52, Moscow Healthcare Department; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
Russian Federation
Russian Federation
3 Pekhotnaya St., Moscow 123182; Build. 2, 8 Trubetskaya St., Moscow 119991
T. N. Tolstykh
City Clinical Hospital No. 52, Moscow Healthcare Department; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
Russian Federation
Russian Federation
3 Pekhotnaya St., Moscow 123182; Build. 2, 8 Trubetskaya St., Moscow 119991
E. A. Baryakh
City Clinical Hospital No. 52, Moscow Healthcare Department; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University); Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia; N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
3 Pekhotnaya St., Moscow 123182; Build. 2, 8 Trubetskaya St., Moscow 119991; Build. 1, 2/1 Barrikadnaya St., Moscow 125993; 1 Ostrovityanova St., Moscow 117997
K. V. Yatskov
City Clinical Hospital No. 52, Moscow Healthcare Department
Russian Federation
Russian Federation
3 Pekhotnaya St., Moscow 123182
E. A. Karimova
City Clinical Hospital No. 52, Moscow Healthcare Department
Russian Federation
Russian Federation
3 Pekhotnaya St., Moscow 123182
A. B. Makeshova
City Clinical Hospital No. 52, Moscow Healthcare Department; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
Russian Federation
Russian Federation
3 Pekhotnaya St., Moscow 123182; Build. 2, 8 Trubetskaya St., Moscow 119991
M. A. Mingalimov
City Clinical Hospital No. 52, Moscow Healthcare Department; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University); State Scientific Center of the Russian Federation – A.I. Burnazyan Federal Medical Biophysical Center, Federal Medical and Biological Agency of Russia
Russian Federation
Russian Federation
3 Pekhotnaya St., Moscow 123182; Build. 2, 8 Trubetskaya St., Moscow 119991; 46 Zhivopisnaya St., Moscow 123098
T. S. Chudnova
City Clinical Hospital No. 52, Moscow Healthcare Department; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University); State Scientific Center of the Russian Federation – A.I. Burnazyan Federal Medical Biophysical Center, Federal Medical and Biological Agency of Russia
Russian Federation
Russian Federation
3 Pekhotnaya St., Moscow 123182; Build. 2, 8 Trubetskaya St., Moscow 119991; 46 Zhivopisnaya St., Moscow 123098
D. D. Ivanova
City Clinical Hospital No. 52, Moscow Healthcare Department
Russian Federation
Russian Federation
3 Pekhotnaya St., Moscow 123182
A. I. Koneva
City Clinical Hospital No. 52, Moscow Healthcare Department
Russian Federation
Russian Federation
3 Pekhotnaya St., Moscow 123182
O. L. Kochneva
City Clinical Hospital No. 52, Moscow Healthcare Department
Russian Federation
Russian Federation
3 Pekhotnaya St., Moscow 123182
E. N. Zotina
City Clinical Hospital No. 52, Moscow Healthcare Department; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
Russian Federation
Russian Federation
3 Pekhotnaya St., Moscow 123182; Build. 2, 8 Trubetskaya St., Moscow 119991
E. Yu. Grishina
City Clinical Hospital No. 52, Moscow Healthcare Department; State Scientific Center of the Russian Federation – A.I. Burnazyan Federal Medical Biophysical Center, Federal Medical and Biological Agency of Russia
Russian Federation
Russian Federation
3 Pekhotnaya St., Moscow 123182; 46 Zhivopisnaya St., Moscow 123098
L. T. Shimanovskaya
City Clinical Hospital No. 52, Moscow Healthcare Department; State Scientific Center of the Russian Federation – A.I. Burnazyan Federal Medical Biophysical Center, Federal Medical and Biological Agency of Russia
Russian Federation
Russian Federation
3 Pekhotnaya St., Moscow 123182; 46 Zhivopisnaya St., Moscow 123098
V. N. Yakimets
City Clinical Hospital No. 52, Moscow Healthcare Department; State Scientific Center of the Russian Federation – A.I. Burnazyan Federal Medical Biophysical Center, Federal Medical and Biological Agency of Russia
Russian Federation
Russian Federation
3 Pekhotnaya St., Moscow 123182; 46 Zhivopisnaya St., Moscow 123098
E. I. Zhelnova
City Clinical Hospital No. 52, Moscow Healthcare Department
Russian Federation
Russian Federation
3 Pekhotnaya St., Moscow 123182
References
1. Program treatment of blood system diseases. Diagnostic algorithms and treatment protocols for blood system diseases. Ed.: V.G. Savchenko. Moscow: Praktika, 2012, 1056 p. (In Russ.).
2. Döhner H., Estey E., Grimwade D. et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 2022;140(12):1345–77. DOI: 10.1182/blood.2022016867
3. Tolstykh T.N., Baryakh E.A., Gagloeva D.E. et al. Management of patients with coronavirus infection and acute myeloid leukemia. Gematologiya i transfuziologiya = Hematology and transfusiology 2023;68(2):53. (In Russ.).
4. Zakurdaeva K., Gavrilina O.A., Vasileva A.N., Dubov S. COVID-19 and hematologic diseases: risk factors and longterm followup of CHRONOS19 Registry. J Clin Oncol 2021;39(15_suppl). DOI: 10.1200/JCO.2021.39.15_suppl.e18715
5. Palanques-Pastor T., Megías-Vericat J.E., Martínez P. Characteristics, clinical outcomes, and risk factors of SARSCOV2 infection in adult acute myeloid leukemia patients: experience of the PETHEMA group. Leuk Lymphoma 2021;62(12):2928–38. DOI: 10.1080/10428194.2021.1948031
6. Fagundes E.M., Neto N.N., Caldas L.M. Mortality by COVID-19 in adults with acute myeloid leukemia: a survey with hematologists in Brazil. Ann Hematol 2021;101(4):923–5. DOI: 10.1007/s00277-021-04659-w
7. Ghandili S., Pfefferle S., Roedl K. Challenges in treatment of patients with acute leukemia and COVID19: a series of 12 patients. Blood Adv 2020;4(23):5936–41. DOI: 10.1182/bloodadvances.2020002543
8. Taurino D., Frigeni M., Grassi A. Concurrent diagnosis of acute myeloid leukemia and symptomatic COVID19 infection: a case report successfully treated with azacitidinevenetoclax combination. Mediterr J Hematol Infect Dis 2021;13(1):e2021057. DOI: 10.4084/MJHID.2021.057
9. Ferrara F., Zappasodi P., Roncoroni E. et al. Impact of COVID-19 on the treatment of acute myeloid leukemia. Leukemia 2020;34(8):2254–6. DOI: 10.1038/s41375-020-0925-7
10. Núñez-Torrón C., García-Gutiérrez V., Tenorio-Núñez M.C. et al. Poor outcome in patients with acute leukemia on intensive chemotherapy and COVID-19. Bone Marrow Transplant 2021;56(1):267–9. DOI: 10.1016/j.clml.2021.01.004
11. Singh S., Singh J., Paul D., Jain K. Treatment of acute leukemia during COVID-19: focused review of evidence. Clin Lymphoma Myeloma Leuk 2021;21(5):289–94. DOI: 10.1016/j.clml.2021.01.004
12. Demichelis-Gómez R., Alvarado-Ibarra M., Vasquez-Chávez J. Treating acute leukemia during the COVID-19 pandemic in an environment with limited resources: a multicenter experience in four Latin American countries. JCO Glob Oncol 2021;7:577–84. DOI: 10.1200/GO.20.00620
13. Buyuktas D., Acar K., Sucak G. COVID-19 infection in patients with acute leukemia: Istanbul experience. Al J Blood Res 2021;11(4):427–37.
14. Marchesi F., SalmantonGarcía J., Emarah Z. et al. COVID-19 in adult acute myeloid leukemia patients: a longterm followup study from the European Hematology Association survey (EPICOVIDEHA). Haematologica 2023;108(1):22–33. DOI: 10.3324/haematol.2022.280847
Review
For citations:
Gagloeva D.E., Misyurina E.N., Tolstykh T.N., Baryakh E.A., Yatskov K.V., Karimova E.A., Makeshova A.B., Mingalimov M.A., Chudnova T.S., Ivanova D.D., Koneva A.I., Kochneva O.L., Zotina E.N., Grishina E.Yu., Shimanovskaya L.T., Yakimets V.N., Zhelnova E.I. Treatment features of adult patients with acute myeloid leukemia during the COVID-19 pandemic. Oncohematology. 2023;18(4):40-44. (In Russ.) https://doi.org/10.17650/1818-8346-2023-18-4(Suppl)-40-44
Views:
2243
Email this article 